Abstract
The volume of research undertaken on the genetic susceptibility of inflammatory bowel disease (IBD) has been tremendous. Genome-wide linkage studies pointed towards more than 10 chromosomal regions and fine-mapping of these regions led to the identification of a number of genes, including CARD15 (NOD2), DLG5, OCTN1 and 2, TLR4 and CARD4 (NOD1). With the recent completion of the human genome project, whole genome association studies (WGAS) have now become possible and have identified additional genes (IL23R, IRGM, PTGER4, ATG16L1) for Crohns disease and ulcerative colitis, that have subsequently been replicated. At present, the CARD15 gene is still the most understood susceptibility gene, explaining around 20% of the genetic predisposition to Crohns disease. Prediction of disease phenotype and response to the main therapies has for many years been a dream for physicians treating IBD patients. Only now, we start to accumulate some evidence proving that genetic factors indeed influence both the clinical course of IBD patients and their likelihood of responding to certain therapies. In the coming years, we expect an exponential increase in the efforts devoted to research in this area. The optimal prediction of both disease behaviour and response to therapy might result from complex combinations of clinical, biochemical, serological and genetic factors.
Keywords: CARD15 Gene, NOD2 protein, pattern recognition receptors, MDR1 polymorphisms, interleukin 23 receptor, immunosuppressive therapy
Current Drug Targets
Title: The Role of Genetics in Inflammatory Bowel Disease
Volume: 9 Issue: 5
Author(s): Liesbet Henckaerts, Carolina Figueroa, Severine Vermeire and Miquel Sans
Affiliation:
Keywords: CARD15 Gene, NOD2 protein, pattern recognition receptors, MDR1 polymorphisms, interleukin 23 receptor, immunosuppressive therapy
Abstract: The volume of research undertaken on the genetic susceptibility of inflammatory bowel disease (IBD) has been tremendous. Genome-wide linkage studies pointed towards more than 10 chromosomal regions and fine-mapping of these regions led to the identification of a number of genes, including CARD15 (NOD2), DLG5, OCTN1 and 2, TLR4 and CARD4 (NOD1). With the recent completion of the human genome project, whole genome association studies (WGAS) have now become possible and have identified additional genes (IL23R, IRGM, PTGER4, ATG16L1) for Crohns disease and ulcerative colitis, that have subsequently been replicated. At present, the CARD15 gene is still the most understood susceptibility gene, explaining around 20% of the genetic predisposition to Crohns disease. Prediction of disease phenotype and response to the main therapies has for many years been a dream for physicians treating IBD patients. Only now, we start to accumulate some evidence proving that genetic factors indeed influence both the clinical course of IBD patients and their likelihood of responding to certain therapies. In the coming years, we expect an exponential increase in the efforts devoted to research in this area. The optimal prediction of both disease behaviour and response to therapy might result from complex combinations of clinical, biochemical, serological and genetic factors.
Export Options
About this article
Cite this article as:
Henckaerts Liesbet, Figueroa Carolina, Vermeire Severine and Sans Miquel, The Role of Genetics in Inflammatory Bowel Disease, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221161
DOI https://dx.doi.org/10.2174/138945008784221161 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Olfactory Receptor Multigene Family in Vertebrates: From the Viewpoint of Evolutionary Genomics
Current Genomics Structure and Function of Ligand CX3CL1 and its Receptor CX3CR1 in Cancer
Current Medicinal Chemistry New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Patent Selections
Recent Patents on Anti-Infective Drug Discovery Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Fibroblast Growth Factor 21 (FGF21) on Energy Balance, Glucose and Lipid Metabolism
Current Diabetes Reviews Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications
Infectious Disorders - Drug Targets Methods for Biomarker Verification and Assay Development
Current Proteomics Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Regulation of FoxP3-Expressing Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery <i>Ovine</i> COX-1 Isoenzyme Bio-production
Current Enzyme Inhibition Peaceful Existence of Tumor Cells with Their Non-malignant Neighbors: The Trade of Tumor Cells with Tumor Microenvironment
Current Chemical Biology Matrix Metalloproteinase-9/Gelatinase B is a Putative Therapeutic Target of Chronic Obstructive Pulmonary Disease and Multiple Sclerosis
Current Pharmaceutical Biotechnology Plant Pathogen Recognition as a Natural, Original and Simple Model for Chemogenomics: A Brief Overview of Cell-Based Assays to Screen for Peptides Acting as Plant Defense Activators
Combinatorial Chemistry & High Throughput Screening Algae, A Possible Source for New Drugs in the Treatment of HIV and Other Viral Diseases
Current Medicinal Chemistry - Anti-Infective Agents Anti-Aggressive, Brain Neurotransmitters and Receptor Binding Study of Fumaria indica in Rodents
Current Psychopharmacology Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Species Differences in Hepatocyte-Directed Gene Transfer: Implications for Clinical Translation
Current Gene Therapy